| Assay ID | Title | Year | Journal | Article |
|---|
| AID1433051 | Antagonist activity at TP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433050 | Antagonist activity at FP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433036 | Clearance in Wistar rat at 0.5 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433060 | Inhibition of human CYP2D6 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433048 | Antagonist activity at EP2 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433044 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as dissociation rate constant by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433054 | Agonist activity at IP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433057 | Toxicity in dog | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433031 | Antagonist activity at DP2 receptor in human whole assessed as inhibition of DK-PGD2-induced eosinophils shape change preincubated for 5 mins followed by DK-PGD2 addition measured after 5 mins by flow cytometry | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433062 | Activation of PXR (unknown origin) assessed as CYP3A4 induction | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433052 | Agonist activity at EP3 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433049 | Antagonist activity at EP4 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433037 | Volume of distribution at steady state in Wistar rat at 0.5 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433030 | Antagonist activity at DP2 receptor in human isolated eosinophils assessed as inhibition of DK-PGD2-induced shape change preincubated for 5 mins followed by DK-PGD2 addition measured after 5 mins by flow cytometry | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433034 | Fraction unbound in plasma of Sprague-Dawley rat DK-PGD2-induced pulmonary eosinophilia mechanistic model at 0.03 to 0.1 mg/kg, po by equilibrium dialysis method | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433047 | Antagonist activity at DP1 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433045 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as dissociation half life by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433038 | Half life in Wistar rat at 0.5 mg/kg, iv by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433046 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433040 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of DK-PGD2-induced IL-5 production after 6 to 8 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433042 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of PGD2-induced IL-4 production preincubated for 30 mins followed by PGD2 addition measured after 6 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433061 | Inhibition of human CYP3A4 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433032 | In vivo antagonist activity at DP2 receptor in Sprague-Dawley rat DK-PGD2-induced pulmonary eosinophilia mechanistic model assessed inhibition of eosinophilia in broncho alveolar lavage fluid at 0.03 to 0.1 mg/kg, po pretreated for 40 mins starting at 2 h | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433029 | Displacement of [3H]PGD2 from human DP2 receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433058 | Inhibition of human CYP1A2 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433043 | Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as association rate constant by TopCount scintillation assay | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433041 | Antagonist activity at DP2 receptor in CD4-positive human TH2 cells assessed as inhibition of DK-PGD2-induced IL-13 production after 6 to 8 hrs | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433055 | Antagonist activity at IP receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433056 | Toxicity in rat | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433059 | Inhibition of human CYP2C9 | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433039 | Oral bioavailability in Wistar rat at 3 mg/kg by LC-MS/MS analysis | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1433053 | Antagonist activity at EP3 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
| Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
| AID1346326 | Human DP2 receptor (Prostanoid receptors) | 2016 | Molecular pharmacology, May, Volume: 89, Issue:5
| Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |